[1] Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016. 66(6): 443-459.
[2] Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004. 103(1): 275-82.
[3] Xu PP, Fu D, Li JY, et al. Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial. Lancet Haematol. 2019. 6(6): e328-e337.
[4] Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018. 50(1): 74-87.
[5] Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020. 38(27): 3119-3128.
[6] Nielsen SJ, Schneider R, Bauer UM, et al. Rb targets histone H3 methylation and HP1 to promoters. Nature. 2001. 412(6846): 561-5.
[7] Dodge JE, Kang YK, Beppu H, Lei H, Li E. Histone H3-K9 methyltransferase ESET is essential for early development. Mol Cell Biol. 2004. 24(6): 2478-86.
[8] Peters AH, O', Carroll D, et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell. 2001. 107(3): 323-37.
[9] Antunes E, Ottersbach K. The MLL/SET family and haematopoiesis. Biochim Biophys Acta Gene Regul Mech. 2020. 1863(8): 194579.
[10] Cai M, Chen Q, Shen J, Lv C, Cai L. Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer. J Cell Mol Med. 2018. 22(10): 4721-4731.
[11] Chiba T, Saito T, Yuki K, et al. Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma. Int J Cancer. 2015. 136(2): 289-98.
[12] Lu C, Yang D, Klement JD, et al. SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion. Cancer Immunol Res. 2019. 7(3): 414-427.
[13] Mo W, Liu Q, Lin CC, et al. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Clin Cancer Res. 2016. 22(7): 1699-712.
[14] Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017. 45(W1): W98-W102.
[15] Li H, Ning S, Ghandi M, et al. The landscape of cancer cell line metabolism. Nat Med. 2019. 25(5): 850-860.
[16] Ghandi M, Huang FW, Jané-Valbuena J, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019. 569(7757): 503-508.
[17] Chandrashekar DS, Bashel B, Balasubramanya S, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017. 19(8): 649-658.
[18] Storz MN, van de Rijn M, Kim YH, Mraz-Gernhard S, Hoppe RT, Kohler S. Gene expression profiles of cutaneous B cell lymphoma. J Invest Dermatol. 2003. 120(5): 865-70.
[19] Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009. 459(7247): 717-21.
[20] Hossain M, Stillman B. Opposing roles for DNA replication initiator proteins ORC1 and CDC6 in control of Cyclin E gene transcription. Elife. 2016. 5.
[21] Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006. 25(38): 5220-7.
[22] Kim G, Kim JY, Lim SC, Lee KY, Kim O, Choi HS. SUV39H1/DNMT3A-dependent methylation of the RB1 promoter stimulates PIN1 expression and melanoma development. FASEB J. 2018. 32(10): 5647-5660.
[23] Li Y, Yuan YY, Meeran SM, Tollefsbol TO. Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells. Mol Cancer. 2010. 9: 274.
[24] Campaner S, Doni M, Verrecchia A, Fagà G, Bianchi L, Amati B. Myc, Cdk2 and cellular senescence: Old players, new game. Cell Cycle. 2010. 9(18): 3655-61.
[25] Park JW, Bae YS. Dephosphorylation of p53 Ser 392 Enhances Trimethylation of Histone H3 Lys 9 via SUV39h1 Stabilization in CK2 Downregulation-Mediated Senescence. Mol Cells. 2019. 42(11): 773-782.
[26] Reimann M, Lee S, Loddenkemper C, et al. Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell. 2010. 17(3): 262-72.
[27] Milanovic M, Fan D, Belenki D, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018. 553(7686): 96-100.
[28] Mungamuri SK, Qiao RF, Yao S, Manfredi JJ, Gu W, Aaronson SA. USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation. Cell Rep. 2016. 14(11): 2528-37.
[29] Cai L, Ma X, Huang Y, Zou Y, Chen X. Aberrant histone methylation and the effect of Suv39H1 siRNA on gastric carcinoma. Oncol Rep. 2014. 31(6): 2593-600.
[30] Lu C, Klement JD, Yang D, et al. SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth. Cancer Lett. 2020. 476: 87-96.
[31] Yu T, Wang C, Yang J, Guo Y, Wu Y, Li X. Metformin inhibits SUV39H1-mediated migration of prostate cancer cells. Oncogenesis. 2017. 6(5): e324.
[32] Chu W, Zhang X, Qi L, et al. The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer. Cancer Res. 2020. 80(13): 2737-2750.
[33] Liao HF, Lee CC, Hsiao PC, et al. TCH1036, a indeno[1,2-c]quinoline derivative, potentially inhibited the growth of human brain malignant glioma (GBM) 8401 cells via suppression of the expression of Suv39h1 and PARP. Biomed Pharmacother. 2016. 82: 649-59.
[34] Rodrigues C, Pattabiraman C, Vijaykumar A, et al. A SUV39H1-low chromatin state characterises and promotes migratory properties of cervical cancer cells. Exp Cell Res. 2019. 378(2): 206-216.
[35] Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005. 436(7051): 660-5.
[36] Iordanskiy S, Van Duyne R, Sampey GC, et al. Therapeutic doses of irradiation activate viral transcription and induce apoptosis in HIV-1 infected cells. Virology. 2015. 485: 1-15.
[37] Dörr JR, Yu Y, Milanovic M, et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature. 2013. 501(7467): 421-5.
[38] Harro CM, Perez-Sanz J, Costich TL, et al. Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice. J Clin Invest. 2021. 131(3).
[39] Djeghloul D, Kuranda K, Kuzniak I, et al. Age-Associated Decrease of the Histone Methyltransferase SUV39H1 in HSC Perturbs Heterochromatin and B Lymphoid Differentiation. Stem Cell Reports. 2016. 6(6): 970-984.